Published December 2005 | Version v1
Journal article

Use of imaging in the management of malignant pleural mesothelioma

  • 1. Department of Radiology, University Hospitals of Leicester, Leicester (United Kingdom)
  • 2. Clinical PET Centre, Guy's and St Thomas' Hospital, London (United Kingdom)

Description

Malignant pleural mesothelioma (MPM) is an increasingly prevalent tumour. The death rate associated with MPM is predicted to peak in the next 10 years, although radiologists and clinicians will be encountering cases for the next few decades. Contrast-enhanced CT is an established technique for evaluating suspected malignant pleural disease, but MPM can be reliably diagnosed only by histological sampling. However, even with adequate sampling and the use of immunocytochemistry, histological diagnosis is known to be difficult; definitive diagnosis may involve a combination of clinical presentation, radiological and histological appearances. Percutaneous biopsy is a promising technique for sampling the pleura. In view of its pattern of growth, MPM is a challenging disease to image by any method, and it behaves quite differently from lung cancer. This review aims to highlight the practical aspects of assessing malignant pleural mesothelioma

Additional details

Identifiers

DOI
10.1016/j.crad.2005.05.015;
PII
S0009-9260(05)00194-7;

Publishing Information

Journal Title
Clinical Radiology
Journal Volume
60
Journal Issue
12
Journal Page Range
p. 1237-1247
ISSN
0009-9260
CODEN
CLRAAG

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
37077741
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BIOPSY; COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; IMAGES; LUNGS; NEOPLASMS; PLEURA; REVIEWS; SAMPLING
Descriptors DEC
BODY; DIAGNOSTIC TECHNIQUES; DISEASES; DOCUMENT TYPES; MEMBRANES; ORGANS; RESPIRATORY SYSTEM; SEROUS MEMBRANES; TOMOGRAPHY

Optional Information

Copyright
Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.